Introduction
Lacosamide, the R-enantiomer of 2-acetamido-N-benzyl-3-methoxypropionamide, is a newer approved antiepileptic drug (AED) characterized by a novel pharmacodynamic profile. Unlikely traditional sodium channel blockers, which affect the channel fast inactivation, lacosamide selectively enhances the slow inactivation. This mechanism results in stabilization of hyperexcitable neuronal membranes, inhibition of repetitive firing of neurons characteristics of epilepsy, and reduction of long-term channel availability without affecting physiological function [1] . It shows a favorable pharmacokinetic profile including fast absorption rate, minimal protein binding and cytochrome P450 interactions, a low potential for drug interactions; furthermore, the availability in multiple formulations permits flexibility in administration.
Lacosamide was approved as adjunctive treatment for adults with partial onset seizures with or without generalization in 2008, [2] [3] [4] and long-term safety and efficacy of add-on treatment have been widely assessed [5] [6] [7] . Noteworthy, lacosamide has recently received approval for monotherapy by the U.S. Food and Drug Administration [8] . Clinical implications might be really meaningful since the single-drug regimen offers several potential advantages over polytherapy, like a reduced risk of pharmacological interactions or side effects, and an improvement of tolerability and long-term compliance. The aim of this study was thus to evaluate the 1-year efficacy and safety of oral lacosamide as conversion monotherapy in adults patients with partial onset seizures.
Methods

Participants and study outcome
We selected study participants from consecutive patients referred to the Epilepsy Centre of the Ospedali Riuniti of Ancona from January 2010 to June 2013 converted to lacosamide monotherapy after successful response, defined as at least 1-year seizure freedom, to lacosamide as add-on therapy, and withdrawal of the concurrent AED medication. Inclusion criteria were: age >18 Purpose: To evaluate the 1-year efficacy and safety of oral lacosamide as conversion monotherapy in adult patients with partial onset seizures with or without generalization. Method: We prospectively followed-up consecutive patients converted to lacosamide monotherapy after 1-year seizure freedom on lacosamide add-on therapy and withdrawal of the concurrent antiepileptic drug (AED). Seizure occurrence, treatment compliance and drug toxicity were assessed every 3 months up to 1 year. The study outcomes were the retention rate of lacosamide as single AED and the seizure freedom under lacosamide monotherapy at 1 year from withdrawal of background AED. The safety variable was the prevalence of lacosamide related adverse events (AEs). Results: Among the 58 included patients, at 1 year from withdrawal of background medication, 37 (63.8%) retained lacosamide as single AED and 32 (55.2%) were free from seizure occurrence under lacosamide monotherapy throughout the entire follow-up. The history of less than three lifetime AEDs turned out to be significant predictor of seizure freedom (adjusted OR = 6.38, 95% CI 1.85-21.98, p = 0.003). Twelve (20.8%) subjects reported mild to moderate AEs, with the commonest being drowsiness, dizziness, and headache. Conclusion: Conversion to lacosamide monotherapy could be effective and well tolerated in selected adults patients with partial onset seizures who had achieved seizure freedom during lacosamide add-on therapy.
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years, diagnosis of epilepsy with partial-onset seizures (either simple and complex, with or without secondary generalizations) according to the 1981 Classification of Epileptic Seizures from the International League Against Epilepsy (ILAE) [9] , at least one seizure in the 1-year before addition of lacosamide to a stable AED monotherapy regimen assumed at the recommended maintenance dosages, at least 1-year seizure freedom during lacosamide add-on treatment and withdrawal of background AED according to usual clinical practice at the center. Exclusion criteria were history of primary generalized epilepsy, alcoholism, drug abuse, conversion disorders or other non-epileptic ictal events, implanted vagus nerve stimulator. Information obtained for all subjects included demographics, clinical history, types of seizures and epilepsy according to the international criteria [9, 10] , baseline seizure frequency as the number of seizures occurred throughout the 12 months before lacosamide employment (as from patient clinical records or seizures diaries). All patients underwent a clinical evaluation including data collection on seizure occurrence, treatment compliance and drug toxicity every 3 months from conversion to lacosamide monotherapy up to 1 year. The study outcomes were the retention rate of lacosamide as single AED and the seizure freedom under lacosamide monotherapy at 1 year from withdrawal of background AED. The safety variable was the prevalence of lacosamide related adverse events (AEs).
Statistical analysis
Values are presented as mean AE SD or median (interquartile range [IQR]) for continuous variables and as the number (percent) of subjects for categorical variables. Comparisons were made using the Student t-test, Mann-Whitney test or Chi-squared test, as appropriate. Logistic regression analysis was applied to identify potential predictors of seizure freedom; associations with outcome that were biologically plausible were identified for statistical analysis. Selected variables were type of epilepsy, number of lifetime AEDs (one or two vs. three or more), seizure frequency (as number of seizures) during the 12 months before lacosamide employment.
Results were considered significant for p values < 0.05 (two sided). Data analysis was performed using STATA/IC 13.1.
Standard protocol approvals, registrations, and patient consents
The local ethical committee approved this study and all participants provided written informed consent in accordance with the Declaration of Helsinki.
Results
A total of 58 Caucasian patients were included in the study. Baseline characteristics are summarized in Table 1 . All patients retained lacosamide at 1-year from withdrawal of background medication, whose 37 (63.8%) as mono-and 21 (36.2%) as polytherapy. AEDs were restarted for the treatment failure of the single drug regimen and within the first 9 months in almost all of the cases (18/21). Among all subjects, 32 (55.2%) were free from seizure occurrence under lacosamide monotherapy throughout the 12-month follow-up; a reduction of seizure frequency !75% compared to the 1-year before employment of lacosamide occurred in the remaining five (8.6%) subjects taking lacosamide Table 1 Baseline demographics and epilepsy characteristics. Twelve (20.8%) subjects reported mild to moderate AEs. The most common were drowsiness (n = 7), dizziness (n = 3), and headache (n = 2). No serious AEs were experienced.
Discussion
The major finding of this study was that lacosamide as monotherapy could be effective and well tolerated in adult patients with partial onset seizures who had successfully responded to lacosamide add-on therapy after failure of previous antiepileptic treatment. At 1-year from withdrawal of background AED, over 60% of the patients retained lacosamide as single drug and more than half of the subjects were free from seizure occurrence under lacosamide monotherapy. Additionally, the likelihood of seizure control increased if lacosamide had been successfully added in early phase when less than three pharmacological attempts had been made.
Little evidence exists about the use of lacosamide as single AED, and comparisons between investigations are hampered by the differences in patient selection and study design. According to a post hoc analysis of the historical-controlled conversion to lacosamide monotherapy study [8] , seizure freedom and reduction of seizure frequency greater than 50% compared to baseline occurred in near to 15% and in the 60% of the subjects completing the monotherapy phase, respectively. Notably, the study by Wechsler et al. [8] strongly differed from the present one for the high proportion of patients somewhat more drug resistant than would usually be considered for monotheraphy in clinical practice, characterized by high baseline seizure frequency, history of three or more lifetime AEDs or concomitant treatment with more than one AED, and for the conversion to single-drug regimen despite the response obtained throughout the maintenance phase. On the other side, our findings are partly consistent with a recent open label extension trial reporting a 50-100% reduction in monthly seizure frequency in almost all patients converted to lacosamide monotherapy [5] . Notably, although the trial involved more than three hundreds of patients, data on monotherapy have been derived from less than 10 subjects.
The safety profile of lacosamide overlapped consistently the current knowledge, with drowsiness and dizziness being among the commonest AEs. As expected, rate and severity of AEs were lower than in lacosamide adjunctive therapy studies. The incidence of AEs is in fact increased by concurrent medications because of pharmacokinetic and pharmacodynamic interactions, and is higher during titration, while background AEDs are still assumed, than in maintenance phase. Furthermore, AEs occur more frequently within the first weeks of treatment, when discontinuation is thus most likely to occur, and tend to regress over time.
Interpretations of our findings should take into account study limitations as the open label design, the lack of a comparison group, the small sample size, and the quite narrow age range of the included population which restricts generalizability to the middleaged epileptic subjects. Additionally, a low baseline seizure frequency might have biased the assessment of the real effectiveness of lacosamide monotherapy: subjects who had very few seizure episodes over the last year prior to starting to lacosamide might not have any further episodes in the coming year due to remission. In this respect, however, it is noteworthy that only a minority of the cohort presented a very low pre-lacosamide seizure frequency. Furthermore, although fluctuations in seizure frequency normally occur in epilepsy, it is unlikely that a complete spontaneous remission could explain all of the observed improvement taking into account the average duration of epilepsy and that the longer seizures persist, the harder they are to control. In these perspectives, future investigations may be desirable to better estimate the different effect sizes of lacosamide therapy in different cohorts of patients.
Study strengths include the prospective design, the 1-year follow-up, the inclusion of patients in different stages of treatment, the usefulness of efficacy and safety data from a setting closely following routine clinical practice.
In conclusion, our study suggests that conversion to lacosamide monotherapy could provide long term effective seizure control with a satisfactory tolerability in selected patients with partial seizures who had responded to lacosamide add-on regimen. Implications for clinical practice could be relevant since single agent treatment offers several potential advantages over polytherapy: it minimizes the likelihood of side effects, avoids the risk of pharmacological interactions and is expected to improve adherence, retention rate, and health care costs. 
